These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 24969004

  • 1. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.
    Symonds T, Hackford C, Abraham L.
    Value Health; 2014 Jun; 17(4):433-7. PubMed ID: 24969004
    [Abstract] [Full Text] [Related]

  • 2. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
    Stewart KA, Neumann PJ.
    Value Health; 2002 Jun; 5(5):390-7. PubMed ID: 12201856
    [Abstract] [Full Text] [Related]

  • 3. FDA actions against health economic promotions, 2002-2011.
    Neumann PJ, Bliss SK.
    Value Health; 2012 Jun; 15(6):948-53. PubMed ID: 22999146
    [Abstract] [Full Text] [Related]

  • 4. An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021.
    Sams L, Slagle AF, Symonds T, Antonova J, Globe D.
    Value Health; 2023 Dec; 26(12):1675-1680. PubMed ID: 37748736
    [Abstract] [Full Text] [Related]

  • 5. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
    Kim H.
    Int J Health Policy Manag; 2015 Aug 25; 4(12):813-21. PubMed ID: 26673465
    [Abstract] [Full Text] [Related]

  • 6. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
    Cowden AL, Katz KA.
    Br J Dermatol; 2006 May 25; 154(5):950-8. PubMed ID: 16634900
    [Abstract] [Full Text] [Related]

  • 7. Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model.
    Mohite N, Funtanilla V, Muzumdar J, Park T.
    Innov Pharm; 2021 May 25; 12(1):. PubMed ID: 34007685
    [Abstract] [Full Text] [Related]

  • 8. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.
    Nguyen D, Seoane-Vazquez E, Rodriguez-Monguio R, Montagne M.
    BMC Health Serv Res; 2013 Jan 22; 13():27. PubMed ID: 23339419
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Drug Advertising Violations: A Longitudinal Trend Analysis of FDA Enforcement Letters from 2005 to 2019.
    Zagrodney KAP, Sheikhan NY, Pinto A, Sheikhan T, Witek TJ.
    Pharmaceut Med; 2021 Jan 22; 35(1):31-38. PubMed ID: 33453042
    [Abstract] [Full Text] [Related]

  • 11. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
    Bramstedt KA.
    Clin Invest Med; 2004 Jun 22; 27(3):129-34. PubMed ID: 15305804
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Examining the FDA's oversight of direct-to-consumer advertising.
    Gahart MT, Duhamel LM, Dievler A, Price R.
    Health Aff (Millwood); 2003 Jun 22; Suppl Web Exclusives():W3-120-3. PubMed ID: 14527243
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
    Romano CA, Nair S, Delphin ES.
    Anesth Analg; 2018 Mar 22; 126(3):976-982. PubMed ID: 29239950
    [Abstract] [Full Text] [Related]

  • 19. The federal regulation of prescription drug advertising and promotion.
    Kessler DA, Pines WL.
    JAMA; 1990 Nov 14; 264(18):2409-15. PubMed ID: 2231998
    [Abstract] [Full Text] [Related]

  • 20. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
    Salas M, Martin M, Pisu M, McCall E, Zuluaga A, Glasser SP.
    Pharmaceut Med; 2008 Mar 01; 22(2):. PubMed ID: 24353430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.